Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
May 14 2015 - 7:30AM
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today
announced that Moshe Manor, the Company's President and Chief
Executive Officer, will present a corporate overview at the 2015
UBS Global Healthcare Conference and the Jefferies 2015 Global
Healthcare Conference. Details regarding the presentations are as
follows:
2015 UBS Global
Healthcare Conference |
Wednesday, May 20, 2015 at 10:30 AM ET |
The Sheraton New York Times Square Hotel, New
York, NY |
|
Jefferies 2015 Global Healthcare
Conference |
Thursday, June 4, 2015 at 1:00PM PM ET |
The Grand Hyatt Hotel, New York, NY |
A live webcast of each presentation will be available
at www.protalix.com on the event calendar page and a replay of
each conference will be archived and available after the respective
conference.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell-based
expression system, ProCellEx®. Protalix's unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.
Protalix's first product manufactured by ProCellEx, taliglucerase
alfa, was approved for marketing by the U.S. Food and Drug
Administration (FDA) in May 2012,
by Israel's Ministry of Health in September
2012, by the Brazilian National Health Surveillance
Agency (ANVISA) in March 2013, by the Mexican
Federal Commission for the Protection against Sanitary Risk
(COFEPRIS) in April 2013, by the Australian Therapeutic
Goods Administration (TGA) in May 2014 and by the
regulatory authorities of other countries. Marketing
applications for taliglucerase alfa have been filed in additional
territories as well. Protalix has partnered with Pfizer
Inc. for the worldwide development and commercialization of
taliglucerase alfa, excluding Israel and Brazil,
where Protalix retains full rights. Protalix's development
pipeline includes the following product candidates: PRX-102, a
modified version of the recombinant human alpha-GAL-A protein for
the treatment of Fabry disease; PRX-112, an orally-delivered
glucocerebrosidase enzyme that is produced and encapsulated within
carrot cells, also for the treatment of Gaucher disease; PRX-106,
an orally-delivered anti-inflammatory treatment; PRX-110 for the
treatment of Cystic Fibrosis; and others.
CONTACT: Investor Contact
Marcy Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2024 to May 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From May 2023 to May 2024